AMERIPRISE FINANCIAL INC - FATE THERAPEUTICS INC ownership

FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.

Quarter-by-quarter ownership
AMERIPRISE FINANCIAL INC ownership history of FATE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$584,043
-50.5%
275,492
+11.0%
0.00%
Q2 2023$1,180,947
+168.9%
248,098
+222.0%
0.00%
Q1 2023$439,236
+131.2%
77,059
+309.3%
0.00%
Q4 2022$190,000
-90.0%
18,826
-77.9%
0.00%
-100.0%
Q3 2022$1,906,000
-3.7%
85,057
+6.5%
0.00%0.0%
Q2 2022$1,979,000
-27.2%
79,874
+13.9%
0.00%0.0%
Q1 2022$2,719,000
-90.9%
70,132
-86.3%
0.00%
-87.5%
Q4 2021$29,937,000
-36.6%
511,652
-35.8%
0.01%
-46.7%
Q3 2021$47,221,000
-18.6%
796,671
+19.2%
0.02%
-16.7%
Q2 2021$58,016,000
+13.2%
668,448
+7.5%
0.02%
+5.9%
Q1 2021$51,260,000
+113.0%
621,705
+134.9%
0.02%
+88.9%
Q4 2020$24,063,000
+77.7%
264,639
-21.9%
0.01%
+50.0%
Q3 2020$13,543,000
+11.5%
338,825
-4.3%
0.01%
+20.0%
Q2 2020$12,149,000
+8.3%
354,058
-29.9%
0.01%
-16.7%
Q1 2020$11,217,000
-70.6%
505,026
-74.1%
0.01%
-62.5%
Q4 2019$38,168,000
+63.6%
1,950,273
+29.8%
0.02%
+60.0%
Q3 2019$23,335,000
+63.4%
1,502,562
+113.7%
0.01%
+66.7%
Q2 2019$14,277,000
+1556.3%
703,276
+695.9%
0.01%
Q1 2018$862,00088,3640.00%
Other shareholders
FATE THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 3,379,064$131,006,00024.77%
Redmile Group, LLC 12,957,222$502,351,00015.68%
Grosvenor Holdings, L.L.C. 1,037,256$40,214,0007.85%
Casdin Capital, LLC 3,400,000$131,818,0005.91%
Ally Bridge Group (NY) LLC 181,500$7,037,0005.22%
DAFNA Capital Management LLC 500,930$19,421,0005.06%
Deep Track Capital, LP 2,000,000$77,540,0004.97%
Artal Group S.A. 2,000,000$77,540,0003.25%
Tri Locum Partners LP 190,345$7,380,0002.88%
ARK Investment Management 10,988,182$426,012,0001.78%
View complete list of FATE THERAPEUTICS INC shareholders